Navigation Links
ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine
Date:2/11/2011

THOUSAND OAKS, Calif., Feb. 11, 2011 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries. (www.biocentury.com)

The publication noted that, ImmunGene's CEO Sanjay Khare "anticipates licensing deals will be a key part of ImmunGene's strategy. 'We see a potential model where we out-license our cytokine payload technology and in-license antibodies or antibody targets that will deliver the payload to treat cancer and perhaps other diseases,' he said."

Dr. Sanjay Khare also said, "We are pleased to receive recognition from a global biotech publication for ImmunGene's interferon payload technology and pipeline of next generation of armed antibodies for cancer. Our platform technology, available for non-exclusive licensing, offers the possibility of lower doses of drug for clinical efficacy which will result in the lower cost of goods along with patient convenience and may reduce hospitalization cost."

"We are in advanced discussions with several biotech/pharma companies for both product and technology partnerships," Dr. Khare added.

About BioCentury

BioCentury Publications, Inc. is internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date in
'/>"/>

SOURCE ImmunGene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Web Resource for Interferon Research
3. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
4. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
5. Pinpoint precision: Delivering a biochemical payload to 1 cell
6. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
7. Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE)
8. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
9. Cellectis Meganuclease Technology Used to Efficiently Prevent Viral Infection
10. Semiconductor technology for ULSIC and TFT conference
11. Reportlinker Adds Industrial Biotechnology China News 1011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The AMA is pleased to share with the ... Alaska Governor Sean Parnell has signed House Bill 255 ... of Unmanned Aircraft Systems and the continuation of the ... it is, “An Act relating to unmanned aircraft systems; ... system.” It defines State of Alaska laws regarding data ...
(Date:8/21/2014)... Aug. 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... first in class collagenase-based products marketed as XIAFLEX ... the U.S. and XIAPEX ® in the ... a randomized, double-blind Phase 2a study of CCH ... fibrosclerotic panniculopathy. The results showed that all three ...
(Date:8/21/2014)... 2014 2014 Deep Research ... a professional and in-depth research report on ... basic Seaweed Fertilizer information, including Seaweed Fertilizer ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:8/21/2014)... Rochelle, N.Y. (PRWEB) August 21, 2014 ... is the first private college in the Mid-Hudson Region ... College will now begin accepting applications from qualified “high-technology” ... , “We are very pleased to have been selected ... support Governor Cuomo’s transformative initiative to stimulate economic development ...
Breaking Biology Technology:State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3
... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) today ... Small and Mid Cap Growth Conference in Naples, ... 4:40 p.m. EST. Kevin,Hrusovsky, President and CEO of ... business. The live webcast can be accessed at, ...
... Candidate Represents Potential New Short-Course Treatment Option for ... Serious Gram-Positive Skin Infections, Including MRSA, CAMBRIDGE, ... TARG ) announced today that it has,submitted a ... and Drug,Administration (FDA) for its lead antibiotic candidate, ...
... PROENCY will provide real-world clinical data on the ... Boston Scientific,Corporation (NYSE: BSX ) today announced ... PROENCY (PROMUS(TM), ENdeavor(R) and CYpher(R)) European,registry. The registry ... It will collect real-life clinical outcome data for ...
Cached Biology Technology:Targanta Submits Oritavancin New Drug Application 2Targanta Submits Oritavancin New Drug Application 3Targanta Submits Oritavancin New Drug Application 4Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4
(Date:8/22/2014)... , August 22, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the addition ... America 2014-2018"  report to their offering.  ... , ,Biometrics is a technology that ... based on their physical or behavioral ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... at the 29th Annual International Papillomavirus Conference shows ... Inc. combats three types of human papillomavirus, including ... cervical cancer. , When tested in several cultured ... HPV-16, HPV-18 and HPV-11 cells, according to Louise ... presented the findings at the Seattle conference. The ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... University scientist Chittaranjan Kole was awarded the Outstanding Crop ... He was one of three scientists to receive the ... the field of crop science. He also chaired a ... this month, "Genomics and Breeding of Climate Resilient ...
... out of research conducted on the edge of the ... Gorge in Tanzania since that produced by Louis and ... special issue of the prestigious Journal of Human ... the Bernard Price Institute for Palaeontological Research, and Professor ...
... consumer products such as shampoos, gels, hair dyes and ... food crops, as reported in a paper in the ... of Sciences . Manufactured nanomaterials are man-made materials ... scale. Their effects on human health and the environment ...
Cached Biology News:Dawn of humanity illuminated in special journal edition 50 years after the Leakeys 2Soybeans susceptible to man-made materials in soil 2Soybeans susceptible to man-made materials in soil 3
... Simultaneously perform 96 assays on four ... four microarray slides with 96 (6mm x ... protein, gene expression, or screening analysis studies. ... compression fit gasket, eliminating the presence of ...
... is an automated multiplexing platform that uses ... pathogen sequence detection and pharmacogenetics applications. Multiple ... to an open and flexible electronic microarray, ... until all tests sites have been utilized. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
Biology Products: